Your browser doesn't support javascript.
loading
Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
Reither, Klaus; Katsoulis, Lynn; Beattie, Trevor; Gardiner, Nicolene; Lenz, Nicole; Said, Khadija; Mfinanga, Elirehema; Pohl, Christian; Fielding, Katherine L; Jeffery, Hannah; Kagina, Benjamin M; Hughes, Elisabeth J; Scriba, Thomas J; Hanekom, Willem A; Hoff, Søren T; Bang, Peter; Kromann, Ingrid; Daubenberger, Claudia; Andersen, Peter; Churchyard, Gavin J.
  • Reither K; Swiss Tropical and Public Health Institute, Basel, Switzerland; University Basel, Basel, Switzerland; Ifakara Health Institute, Bagamoyo, Tanzania.
  • Katsoulis L; Aurum Institute, Johannesburg, South Africa.
  • Beattie T; Aurum Institute, Johannesburg, South Africa.
  • Gardiner N; Aurum Institute, Johannesburg, South Africa.
  • Lenz N; Swiss Tropical and Public Health Institute, Basel, Switzerland; University Basel, Basel, Switzerland.
  • Said K; Ifakara Health Institute, Bagamoyo, Tanzania.
  • Mfinanga E; Ifakara Health Institute, Bagamoyo, Tanzania.
  • Pohl C; Swiss Tropical and Public Health Institute, Basel, Switzerland; University Basel, Basel, Switzerland; Ifakara Health Institute, Bagamoyo, Tanzania.
  • Fielding KL; London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Jeffery H; London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Kagina BM; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
  • Hughes EJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
  • Hanekom WA; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
  • Hoff ST; Statens Serum Institute, Department of Infectious Disease Immunology, Copenhagen, Denmark.
  • Bang P; Statens Serum Institute, Department of Vaccine Development, Copenhagen, Denmark.
  • Kromann I; Statens Serum Institute, Department of Vaccine Development, Copenhagen, Denmark.
  • Daubenberger C; Swiss Tropical and Public Health Institute, Basel, Switzerland; University Basel, Basel, Switzerland.
  • Andersen P; Statens Serum Institute, Department of Infectious Disease Immunology, Copenhagen, Denmark.
  • Churchyard GJ; Aurum Institute, Johannesburg, South Africa; London School of Hygiene and Tropical Medicine, London, United Kingdom; School of Public Health, University of Witwatersrand, Johannesburg, South Africa.
PLoS One ; 9(12): e114602, 2014.
Article en En | MEDLINE | ID: mdl-25490675
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis / Infecciones por VIH / Vacunas contra la Tuberculosis Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis / Infecciones por VIH / Vacunas contra la Tuberculosis Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male Idioma: En Año: 2014 Tipo del documento: Article